US 20220119504A1

(19) United States

(12) Patent Application Publication

Nussenzweig et al.

(10) Pub. No.: US 2022/0119504 A1

(43) Pub. Date: Apr. 21, 2022

(54) **ANTI-HIV ANTIBODY 10-1074 VARIANTS**

(71) Applicant: **The Rockefeller University**, New York, NY (US)

(72) Inventors: **Michel Nussenzweig**, New York, NY (US); **Randal R. Ketchem**, Snohomish, WA (US); **Christine C. Siska**, Seattle, WA (US); **Alison J. Gillespie**, Seattle, WA (US); **Rutilio H. Clark**, Bainbridge Island, WA (US); **Bruce A. Kerwin**, Bainbridge Island, WA (US)

(21) Appl. No.: **17/275,310**

(22) PCT Filed: **Sep. 12, 2019**

(86) PCT No.: **PCT/US19/50823**

§ 371 (c)(1),
(2) Date: **Mar. 11, 2021**

Related U.S. Application Data

(60) Provisional application No. 62/731,356, filed on Sep. 14, 2018.

Publication Classification

(51) **Int. Cl.**

C07K 16/10	(2006.01)
A61K 45/06	(2006.01)
A61P 31/18	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 16/1045*** (2013.01); *A61K 2039/507* (2013.01); ***A61P 31/18*** (2018.01); ***A61K 45/06*** (2013.01)

(57) **ABSTRACT**

The present disclosure provides optimized broadly-neutralizing anti-HIV antibodies, having modified light chain variable regions and/or heavy chain variable regions leading to improved biophysical characteristics. The present disclosure also provides methods for producing these anti-HIV antibodies and methods of use thereof.

Specification includes a Sequence Listing.